Critics, including Bright, who opposed funding the trial while director at HHS' Biomedical Advanced Research and Development Authority, or BARDA, ...
News
- Pepcid-COVID study raised red flags weeks after $21M grant
- Initial public offerings scheduled to debut next week
Business: Phase 2 biotech developing allogeneic T cell therapies for viral diseases. Fathom Holdings - Cary, N.C., 2.5 million shares, priced $7-$9, ...
- Coronavirus makes changes that cause cells not to recognize it
The University of Texas Health Science Center at San Antonio, also ... health professions and graduate biomedical sciences have graduated more ...
- Pepcid as a virus remedy? Trump admin's $21M gamble fizzled
Federal pandemic response scientists at the Biomedical Advanced Research and Development Authority, or BARDA, were shut out of these early ...
- Trump to visit North Carolina, cite work on COVID-19 vaccine
The biotechnology facility Trump will visit is the FUJIFILM Diosynth Biotechnologies' Innovation Center in Morrisville, a suburb of Raleigh. The White ...